Completed NA INTERVENTIONAL 1-arm NCT04223492

Liquid Biopsies and Imaging in Breast Cancer (LIMA)

Sponsor: ALS Automated Lab Solutions GmbH

Interventions Liquid biopsy Multi-parametric MRI

Updated 7 times since 2020 Last updated: Dec 21, 2023 Started: Jan 2, 2019 Primary completion: May 16, 2022 Completion: May 16, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04223492, this NA trial focuses on Breast Cancer and remains completed. Sponsored by ALS Automated Lab Solutions GmbH, it has been updated 7 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Mar 2025 — Present [monthly]

Completed NA
Sep 2024 — Mar 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2024 — Jul 2024 [monthly]

Completed NA

Status: Unknown Status → Completed
Jan 2022 — Jan 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Jan 2022 [monthly]

Recruiting NA
Feb 2020 — Jan 2021 [monthly]

Recruiting NA

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ALS Automated Lab Solutions GmbH
ANGLE Europe Limited
Agena Bioscience GmbH
DiaDx
Horizon 2020 - European Commission
Institut National de la Santé Et de la Recherche Médicale, France
Institut du Cancer de Montpellier - Val d'Aurelle
Philips Electronics Nederland BV
Philips GmbH Innovate Technologies
Stilla Technologies
UMC Utrecht

Data source: UMC Utrecht

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Utrecht, Netherlands